Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cyclerion Therapeutics, Inc. CYCN
$0.25
-$0.02 (-9.19%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
13405669.00000000
-
week52high
1.25
-
week52low
0.23
-
Revenue
-1328000
-
P/E TTM
0
-
Beta
1.94071600
-
EPS
-0.93000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мар 2023 г. в 20:40
Описание компании
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | 20 окт 2021 г. | |
| Cantor Fitzgerald | Overweight | 24 сент 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hyman Steven | A | 57753 | 57753 | 25 июл 2022 г. |
| DESOUZA ERROL B | A | 20000 | 20000 | 14 июн 2022 г. |
| Isacson Ole | A | 20000 | 20000 | 14 июн 2022 г. |
| CONRADES GEORGE H | A | 20000 | 20000 | 14 июн 2022 г. |
| Lovell Stephanie | A | 20000 | 20000 | 14 июн 2022 г. |
| Fanucci Marsha | A | 20000 | 20000 | 14 июн 2022 г. |
| Mendelsohn Michael | A | 20000 | 20000 | 14 июн 2022 г. |
| MCGUIRE TERRANCE | A | 20000 | 20000 | 14 июн 2022 г. |
| Busch Andreas | A | 135000 | 135000 | 20 янв 2022 г. |
| Gjino Anjeza | A | 135000 | 135000 | 20 янв 2022 г. |
Новостная лента
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
09 авг 2022 г. в 18:48
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?